- Home
- MBIN vs HCM Comparison
MBIN vs HCM Comparison
Compare MBIN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIN | HCM |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | Hong Kong |
| Employees | 735 | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MBIN | HCM |
|---|---|---|
| Price | $48.09 | $10.16 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $43.67 | $13.75 |
| AVG Volume (30 Days) | ★ 89.3K | 56.4K |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.76 | $20.60 |
| Revenue Next Year | $3.73 | $15.62 |
| P/E Ratio | $12.29 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.75 | $10.40 |
| 52 Week High | $51.00 | $19.50 |
Technical Indicators
Market Signals| Indicator | MBIN | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 23.96 |
| Support Level | $44.97 | N/A |
| Resistance Level | $48.50 | $15.59 |
| Average True Range (ATR) | 1.46 | 0.31 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 51.08 | 5.85 |
Price Performance
Historical ComparisonAbout MBIN Merchants Bancorp
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.